Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
基本信息
- 批准号:10412909
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-10-01 至 2023-09-30
- 项目状态:已结题
- 来源:
- 关键词:ADME StudyAccountingAddressAggressive Clinical CourseAmericanAntiestrogen TherapyAromatase InhibitorsBiochemicalBiological MarkersBiological ModelsBreast Cancer ModelBreast Cancer PreventionBreast Cancer TreatmentBreast Cancer therapyCancer EtiologyCaringCessation of lifeClinicalClinical TreatmentCouplesDevelopmentDiagnosisDoseDrug KineticsEnvironmentEpigenetic ProcessEstrogen AntagonistsEstrogen receptor positiveExhibitsFemaleGeneral PopulationGlutamic AcidGoalsHealthcare SystemsIn VitroIncidenceKnowledgeLeadLeucineLiposomesMalignant NeoplasmsMass Spectrum AnalysisMaximum Tolerated DoseMediatingMilitary PersonnelModelingModificationMolecularMolecular Mechanisms of ActionNeoplasm MetastasisNuclear ReceptorsOncogenicOutcomePatientsPharmaceutical PreparationsPlayPopulationPre-Clinical ModelPrevalencePreventionProlineProteinsProto-OncogenesRepressionResearchResistanceResistance developmentRoleSignal TransductionSmall Interfering RNASouth TexasSpecificityTechnologyTestingTexasTherapeuticToxic effectVeteransWomanWorkXenograft procedureadvanced breast cancerbreast cancer progressionbreast cancer survivalcancer diagnosiscancer therapyclinically relevantclinically significantcost effectiveeffective therapyefficacy testinggenome sequencinghistone modificationin vitro Modelin vivoin vivo evaluationinhibitorinnovationknock-downmalignant breast neoplasmmilitary veteranmolecular subtypesmortalitynew therapeutic targetnovel therapeuticspatient derived xenograft modelpeptidomimeticspreventprognostic indicatorprogramsreceptor functionresponsesmall moleculesmall molecule inhibitortargeted cancer therapytargeted treatmenttherapeutic targettherapy developmenttherapy resistanttriple-negative invasive breast carcinomatumortumor progressiontumor xenograftwhole genome
项目摘要
Project summary
Breast cancer (BCa) is the second leading cause of cancer death in women. Among Servicewomen, BCa is the
most commonly diagnosed cancer, accounting for 30% of female cancers with increased prevalence in older
Veterans. BCa has distinct molecular subtypes; estrogen receptor (ER) positive and triple negative breast
cancer (TNBC). A significant portion of ER-positive BCa initially respond to anti-estrogens or aromatase inhibitors
but eventually exhibit unresponsiveness to therapy, develop therapy-resistant breast cancer (TR-BC), and
ultimately progress to incurable metastasis. Moreover, TNBC has a more aggressive clinical course and overall
lack of targeted therapies. Development of effective therapies for female Veterans with TR-BC or TNBC
represents the highest unmet need in breast cancer treatment. Our ongoing research on PELP1, an oncogenic
coregulator protein originally cloned in this lab, displays an integral role in multiple nuclear receptor (NR)
functions associated with BCa progression. PELP1 expression is commonly dysregulated in BCa eliciting a
conducive environment for epigenetic modifications. Concomitantly, PELP1 is a prognostic indicator for poorer
BCa survival and indicator of therapy resistance and metastases. We have developed a first-in-class small
molecule inhibitor of PELP1 (SMIP) displaying effectivity against TR-BC and TNBC. SMIPs block PELP1’s ability
to promote epigenetic modifications. The objective of this proposal is to further develop a lead SMIP into a novel
drug for the clinical treatment of TR-BC and TNBC. Our overarching hypothesis is that PELP1 couples NRs
with epigenetic modifiers; therefore, targeting the PELP1 axis with SMIPs will have a therapeutic utility in treating
both TR-BC and TNBC. In Aim 1, we will determine lead SMIPs mechanism of action using biochemical,
molecular, unbiased mass spectroscopy, and whole genome sequencing approaches. In Aim 2, we will optimize
SMIP derivatives and conduct studies establishing the maximum tolerated dose and dose efficacy in vivo using
TR-BC and TNBC models. In Aim 3, we will test the translatability of optimized SMIPs using therapy resistant
xenografts, metastatic models, and patient derived xenografts (PDX). This proposal is innovative as SMIPs block
signaling from multiple oncogenic PELP1 activated NRs to uniquely promote repression of epigenetic modifiers.
Successful completion of the proposed work will result in the development of a first-in-class cancer therapy
drug specifically addressing the current lack of TR-BC and TNBC targeted therapies. This research program is
significant as it is expected to aid in identifying therapeutic targets critical to the treatment and prevention of
advanced breast cancer in the population of Servicewomen.
项目总结
乳腺癌(BCA)是女性癌症死亡的第二大原因。在女军人中,BCA是
最常见的确诊癌症,占女性癌症的30%,老年人患病率上升
退伍军人。BCA有不同的分子亚型;雌激素受体(ER)阳性和三重阴性的乳房
癌症(TNBC)。很大一部分ER阳性的BCA最初对抗雌激素或芳香酶抑制剂有反应
但最终表现出对治疗的无反应,发展为耐药乳腺癌(tr-bc),以及
最终发展为无法治愈的转移。此外,TNBC的临床病程和总体上更具侵略性
缺乏针对性的治疗。女性退伍军人合并TRBC或TNBC的有效治疗方法的发展
代表了乳腺癌治疗中未得到满足的最高需求。我们正在进行的关于PELP1的研究,一种致癌的
本实验室首次克隆的辅调节蛋白在多核受体(NR)中起着不可或缺的作用
与BCA进展相关的功能。PELP1在BCA中的表达通常是失调的,导致
有利于表观遗传修饰的环境。同时,PELP1是较差的预后指标
BCA存活率和治疗耐药及转移的指标。我们开发了一款一流的小型
PELP1分子抑制物(SMIP)对tr-bc和tnbc均有抑制作用。SMIP阻断PELP1的S能力
以促进表观遗传修饰。这项提议目标是将一个主要的SMIP进一步发展成一部小说
临床治疗tr-bc和tnbc的药物。我们的主要假设是PELP1将NR
因此,用SMIPs靶向PELP1轴将在治疗中具有治疗作用
包括tr-bc和tnbc。在目标1中,我们将利用生化方法确定铅SMIPs的作用机制,
分子、无偏质谱学和全基因组测序方法。在目标2中,我们将优化
SMIP衍生物,并进行研究,确定体内最大耐受剂量和剂量功效
TR-BC和TNBC模型。在目标3中,我们将使用治疗抵抗来测试优化的SMIP的可译性
异种移植物,转移模型和患者来源的异种移植物(PDX)。这项建议是创新的,因为SMIP阻止
来自多个致癌基因PELP1的信号激活NRs,以独特地促进表观遗传修饰物的抑制。
拟议工作的成功完成将导致开发一流的癌症治疗方法
专门针对目前缺乏tr-bc和tnbc靶向治疗的药物。这项研究计划是
具有重要意义,因为预计它将有助于确定对治疗和预防
服役女性人群中的晚期乳腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ratna K Vadlamudi其他文献
Ratna K Vadlamudi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ratna K Vadlamudi', 18)}}的其他基金
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
- 批准号:
10044416 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
- 批准号:
10516093 - 财政年份:2019
- 资助金额:
-- - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
-- - 项目类别:














{{item.name}}会员




